Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1b/2 first-line study of gocatamig- and ifinatamab deruxtecan-based regimens in extensive-stage small cell lung cancer
MOH_2026-01-03_015578Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gocatamig and ifinatamab deruxtecan in small cell lung cancer (SCLC) (4 arms), sponsored by Merck & Co. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
gocatamigifinatamab deruxtecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2026-01-03_015578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-01-03_015578.